Part II: Carbohydrate Metabolism
The Central Highway of Energy
Carbohydrate metabolism represents the most ancient and universal set of metabolic pathways in biology. From the simplest bacteria to the most complex multicellular organisms, the breakdown and synthesis of sugars provides the fundamental currency of cellular energy. Glucose, the six-carbon sugar at the heart of these pathways, serves as both a primary fuel and a versatile biosynthetic precursor.
In this part, we trace the complete journey of glucose through glycolysis, examine the metabolic crossroads at pyruvate, explore the reverse synthesis via gluconeogenesis, investigate glycogen as an energy reserve, uncover the pentose phosphate pathway's dual roles, and understand how blood glucose homeostasis is maintained in health and disrupted in disease.
1. Glycolysis — The Universal Pathway
1.1 Overview
Glycolysis (from Greek glykys, "sweet," and lysis, "splitting") is a sequence of ten enzyme-catalyzed reactions that converts one molecule of glucose (6 carbons) into two molecules of pyruvate (3 carbons each), producing a net yield of 2 ATP and 2 NADH. This pathway occurs in the cytoplasm of virtually all living cells and does not require oxygen, making it the primary energy source under anaerobic conditions.
Net Reaction of Glycolysis
\[\text{Glucose} + 2\,\text{NAD}^+ + 2\,\text{ADP} + 2\,P_i \rightarrow 2\,\text{Pyruvate} + 2\,\text{NADH} + 2\,\text{H}^+ + 2\,\text{ATP} + 2\,\text{H}_2\text{O}\]
1.2 Historical Context
The elucidation of glycolysis represents one of the great triumphs of 20th-century biochemistry. Known as the Embden-Meyerhof-Parnas (EMP) pathway, it was pieced together through the combined efforts of Gustav Embden, Otto Meyerhof, and Jakub Parnas between 1905 and 1940. Eduard Buchner's 1897 discovery that cell-free yeast extracts could ferment sugar proved that fermentation was a chemical process, not a vital force — earning him the 1907 Nobel Prize. Arthur Harden and William Young subsequently showed that inorganic phosphate was required, leading to the discovery of sugar phosphate intermediates. Meyerhof received the 1922 Nobel Prize for elucidating the relationship between oxygen consumption and lactic acid production in muscle.
The individual enzymes were isolated and characterized throughout the 1930s and 1940s by a remarkable roster of biochemists. Carl and Gerty Cori identified glucose-1-phosphate ("Cori ester") and elucidated glycogen metabolism. Otto Warburg discovered the role of NAD⁺ (then called "coenzyme I") as a hydrogen carrier. By 1940, the complete pathway from glucose to pyruvate had been established — the first metabolic pathway to be fully elucidated. The glycolytic pathway is now recognized as one of the most ancient and conserved biochemical pathways, present in virtually all domains of life, suggesting it evolved very early in the history of life on Earth, likely before the atmosphere contained significant oxygen.
1.3 The Ten Steps of Glycolysis
Energy Investment Phase (Steps 1–5)
In the preparatory phase, two molecules of ATP are consumed to phosphorylate and rearrange glucose into two molecules of glyceraldehyde-3-phosphate (G3P). This "priming" is essential to destabilize the glucose molecule for subsequent cleavage.
| Step | Enzyme | Reaction | \(\Delta G^{\circ\prime}\) (kJ/mol) |
|---|---|---|---|
| 1 | Hexokinase | Glucose + ATP → Glucose-6-phosphate + ADP | −16.7 |
| 2 | Phosphoglucose isomerase | Glucose-6-phosphate ⇌ Fructose-6-phosphate | +1.7 |
| 3 | Phosphofructokinase-1 (PFK-1) | Fructose-6-phosphate + ATP → Fructose-1,6-bisphosphate + ADP | −14.2 |
| 4 | Aldolase | Fructose-1,6-bisphosphate ⇌ DHAP + Glyceraldehyde-3-phosphate | +23.8 |
| 5 | Triose phosphate isomerase | DHAP ⇌ Glyceraldehyde-3-phosphate | +7.5 |
Energy Payoff Phase (Steps 6–10)
In the payoff phase, each molecule of glyceraldehyde-3-phosphate (two per glucose) is oxidized and rearranged to form pyruvate. This phase generates 4 ATP (via substrate-level phosphorylation) and 2 NADH, yielding a net gain of 2 ATP per glucose.
| Step | Enzyme | Reaction | \(\Delta G^{\circ\prime}\) (kJ/mol) |
|---|---|---|---|
| 6 | Glyceraldehyde-3-phosphate dehydrogenase | G3P + NAD⁺ + Pᵢ ⇌ 1,3-Bisphosphoglycerate + NADH + H⁺ | +6.3 |
| 7 | Phosphoglycerate kinase | 1,3-BPG + ADP → 3-Phosphoglycerate + ATP | −18.5 |
| 8 | Phosphoglycerate mutase | 3-Phosphoglycerate ⇌ 2-Phosphoglycerate | +4.4 |
| 9 | Enolase | 2-Phosphoglycerate ⇌ Phosphoenolpyruvate + H₂O | +7.5 |
| 10 | Pyruvate kinase | PEP + ADP → Pyruvate + ATP | −31.4 |
Energy Balance Summary
Investment phase: 2 ATP consumed (steps 1 and 3)
Payoff phase: 4 ATP produced (steps 7 and 10, ×2 each) + 2 NADH (step 6, ×2)
Net yield: 2 ATP + 2 NADH per glucose
\[\Delta G^{\circ\prime}_{\text{overall}} = -85.0 \text{ kJ/mol}\]
\[\Delta G_{\text{in vivo}} \approx -74 \text{ kJ/mol (erythrocytes)}\]
1.4 Key Regulatory Enzymes
Hexokinase (Step 1)
Catalyzes the first committed step by phosphorylating glucose to glucose-6-phosphate (G6P), trapping it inside the cell. Hexokinase exhibits product inhibition — it is allosterically inhibited by its own product, G6P. This prevents excessive phosphorylation when downstream pathways are saturated. In liver, the isozyme glucokinase (hexokinase IV) has a higher K_m (~10 mM vs ~0.1 mM), allowing the liver to buffer blood glucose after meals.
\[\text{Glucose} + \text{ATP} \xrightarrow{\text{Hexokinase}} \text{G6P} + \text{ADP} \quad \Delta G^{\circ\prime} = -16.7 \text{ kJ/mol}\]
Phosphofructokinase-1 — PFK-1 (Step 3)
PFK-1 is the most important regulatory enzyme of glycolysis and catalyzes the "committed step" of the pathway. It is a tetrameric enzyme subject to extensive allosteric regulation:
- Activators: AMP (signals low energy), fructose-2,6-bisphosphate (F2,6BP — most potent activator), ADP, Pᵢ
- Inhibitors: ATP (at allosteric site — signals high energy), citrate (signals TCA cycle abundance), H⁺ (prevents excess lactate in muscle)
Fructose-2,6-bisphosphate (F2,6BP) is the single most important allosteric regulator. It is produced by phosphofructokinase-2 (PFK-2) and degraded by fructose-2,6-bisphosphatase (FBPase-2), both activities residing on the same bifunctional enzyme. Hormonal control of this enzyme (insulin vs. glucagon) is the primary mechanism for reciprocal regulation of glycolysis and gluconeogenesis.
Pyruvate Kinase (Step 10)
Catalyzes the final step of glycolysis, transferring the phosphoryl group from phosphoenolpyruvate (PEP) to ADP, producing ATP and pyruvate. This is the second substrate-level phosphorylation in glycolysis and is essentially irreversible in vivo (\(\Delta G^{\circ\prime} = -31.4\) kJ/mol).
- Activators: Fructose-1,6-bisphosphate (F1,6BP — feedforward activation)
- Inhibitors: ATP (product inhibition), alanine (signals amino acid abundance), acetyl-CoA, long-chain fatty acids
In the liver, pyruvate kinase (L isozyme) is also regulated by covalent modification: glucagon-stimulated phosphorylation by PKA inactivates it, diverting PEP toward gluconeogenesis during fasting.
\[\text{PEP} + \text{ADP} \xrightarrow{\text{Pyruvate kinase}} \text{Pyruvate} + \text{ATP} \quad \Delta G^{\circ\prime} = -31.4 \text{ kJ/mol}\]
Important Step Details
- Step 1 (Hexokinase): Requires Mg²⁺-ATP as the true substrate. The phosphoryl transfer traps glucose inside the cell since G6P cannot cross the plasma membrane. In liver, glucokinase (hexokinase IV) has a much higher \(K_m\) (~10 mM vs ~0.1 mM for hexokinase I–III), enabling the liver to act as a glucose buffer.
- Step 4 (Aldolase): Despite its very unfavorable \(\Delta G^{\circ\prime} = +23.8\) kJ/mol, this reaction proceeds forward in vivo because the products are rapidly consumed by subsequent reactions, maintaining low product concentrations (Le Chatelier's principle). The actual \(\Delta G\) in the cell is close to zero.
- Step 5 (TPI): Triose phosphate isomerase is a "catalytically perfect" enzyme — its rate is limited only by diffusion of substrate to the active site (\(k_{cat}/K_m \approx 10^8 \text{ M}^{-1}\text{s}^{-1}\)).
- Step 6 (GAPDH): This is the only oxidation step in glycolysis. The aldehyde group of G3P is oxidized while NAD⁺ is reduced to NADH. The energy of oxidation is conserved in the high-energy thioester intermediate and then as the acyl phosphate bond in 1,3-BPG.
- Step 9 (Enolase): Dehydration of 2-phosphoglycerate to PEP redistributes energy within the molecule, raising the phosphoryl group transfer potential from ~17 kJ/mol (in 2-PG) to ~62 kJ/mol (in PEP). Enolase requires Mg²⁺ and is inhibited by fluoride (via formation of a fluorophosphate-Mg complex), which is why blood collection tubes for glucose measurement contain sodium fluoride.
Key Thermodynamic Insight
Of the ten steps, only three are thermodynamically irreversible under cellular conditions (steps 1, 3, and 10). These three reactions are the sites of regulation and represent the "bypass" reactions that gluconeogenesis must circumvent with different enzymes. The remaining seven steps operate near equilibrium and are freely reversible.
\[\Delta G_{\text{total}} = \sum_{i=1}^{10} \Delta G_i = -85.0 \text{ kJ/mol}\]
2. The Fate of Pyruvate
Pyruvate stands at a critical metabolic crossroads. Its fate depends on the organism, the tissue, and the availability of oxygen. Three major routes exist for pyruvate metabolism, each serving distinct physiological needs and occurring in different cellular compartments.
2.1 Three Major Fates of Pyruvate
Fate 1: Aerobic Oxidation — Pyruvate → Acetyl-CoA
Under aerobic conditions in most tissues, pyruvate is transported into the mitochondrial matrix by the mitochondrial pyruvate carrier (MPC) and oxidatively decarboxylated by the pyruvate dehydrogenase complex (PDH). The acetyl-CoA produced enters the TCA cycle for complete oxidation to CO₂.
\[\text{Pyruvate} + \text{CoA} + \text{NAD}^+ \rightarrow \text{Acetyl-CoA} + \text{CO}_2 + \text{NADH}\]
Fate 2: Anaerobic Reduction — Pyruvate → Lactate
Under anaerobic conditions (or in cells lacking mitochondria, such as red blood cells), pyruvate is reduced to L-lactate by lactate dehydrogenase (LDH), with NADH serving as the electron donor. This reaction regenerates NAD⁺, which is essential for glycolysis to continue. Without this regeneration, glycolysis would halt at step 6 due to NAD⁺ depletion.
\[\text{Pyruvate} + \text{NADH} + \text{H}^+ \rightleftharpoons \text{Lactate} + \text{NAD}^+\]
Fate 3: Alcoholic Fermentation — Pyruvate → Ethanol + CO₂
In yeast and some other microorganisms under anaerobic conditions, pyruvate is first decarboxylated to acetaldehyde by pyruvate decarboxylase (requiring thiamine pyrophosphate, TPP), then reduced to ethanol by alcohol dehydrogenase (ADH). This two-step process also regenerates NAD⁺.
\[\text{Pyruvate} \xrightarrow{\text{TPP}} \text{Acetaldehyde} + \text{CO}_2 \xrightarrow{\text{ADH}} \text{Ethanol}\]
2.2 The Pyruvate Dehydrogenase Complex (PDH)
The PDH complex is one of the largest multienzyme complexes known, with a molecular mass of approximately 9.5 MDa in mammals. It consists of multiple copies of three distinct enzymes arranged around a central cubic core, plus two regulatory enzymes:
| Component | Enzyme Name | Cofactor(s) | Function |
|---|---|---|---|
| E1 | Pyruvate dehydrogenase | TPP (thiamine pyrophosphate) | Decarboxylates pyruvate, transfers hydroxyethyl group to lipoamide |
| E2 | Dihydrolipoyl transacetylase | Lipoamide, CoA-SH | Transfers acetyl group to CoA, forming acetyl-CoA |
| E3 | Dihydrolipoyl dehydrogenase | FAD, NAD⁺ | Re-oxidizes dihydrolipoamide, transfers electrons to NAD⁺ |
Overall PDH Reaction
\[\text{Pyruvate} + \text{CoA-SH} + \text{NAD}^+ \rightarrow \text{Acetyl-CoA} + \text{CO}_2 + \text{NADH} + \text{H}^+ \quad \Delta G^{\circ\prime} = -33.4 \text{ kJ/mol}\]
PDH Regulation
The PDH complex is regulated by two mechanisms operating in concert:
- Product inhibition: Acetyl-CoA competes with CoA-SH at E2; NADH competes with NAD⁺ at E3
- Covalent modification: PDH kinase phosphorylates E1 (inactivation); PDH phosphatase dephosphorylates E1 (activation)
PDH kinase is activated by high ratios of [acetyl-CoA]/[CoA], [NADH]/[NAD⁺], and [ATP]/[ADP], signaling energy sufficiency. PDH phosphatase is activated by Ca²⁺ (important in muscle contraction) and insulin (in adipose tissue). This ensures that pyruvate oxidation matches the cell's energy demands.
2.3 The Cori Cycle
During vigorous exercise, skeletal muscle produces lactate faster than it can be oxidized. Lactate is exported to the blood and taken up by the liver, where it is converted back to glucose via gluconeogenesis. This glucose is then released into the blood and returned to muscle. This Cori cycle (described by Carl and Gerty Cori, Nobel Prize 1947) effectively shifts the metabolic burden of gluconeogenesis from muscle to liver.
Cori Cycle Energetics
The Cori cycle is energetically expensive for the whole organism:
- Muscle glycolysis: Glucose → 2 Lactate + 2 ATP
- Liver gluconeogenesis: 2 Lactate → Glucose − 6 ATP equivalents
- Net cost: 4 ATP equivalents per cycle
\[\text{Net: } 6\,\text{ATP}_{\text{liver}} - 2\,\text{ATP}_{\text{muscle}} = 4\,\text{ATP consumed per cycle}\]
2.4 The Warburg Effect
In the 1920s, Otto Warburg observed that cancer cells preferentially metabolize glucose to lactate even in the presence of abundant oxygen — a phenomenon now called the Warburg effect (aerobic glycolysis). Cancer cells may convert up to 85% of their glucose to lactate, compared to <5% in normal cells under aerobic conditions.
Although energetically wasteful (2 ATP per glucose vs. ~30–32 ATP with complete oxidation), the Warburg effect provides several advantages to rapidly dividing cells:
- Faster ATP production rate (glycolysis is ~100× faster than oxidative phosphorylation per unit time)
- Glycolytic intermediates diverted to biosynthetic pathways (nucleotides, amino acids, lipids)
- Acidification of the tumor microenvironment (lactate export) promotes invasion
- Reduced ROS production compared to mitochondrial respiration
This metabolic reprogramming is exploited clinically in PET scanning, where the glucose analog ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) accumulates preferentially in tumors due to their high rates of glucose uptake.
Molecular Drivers of the Warburg Effect
Several oncogenic signaling pathways converge to reprogram glucose metabolism in cancer:
- HIF-1α: Hypoxia-inducible factor induces expression of glucose transporters (GLUT1, GLUT3), glycolytic enzymes, and lactate dehydrogenase A (LDHA), while suppressing mitochondrial biogenesis
- c-Myc: Upregulates GLUT1, hexokinase 2 (HK2), PFK, enolase, and LDHA; also drives glutamine metabolism
- PI3K/Akt/mTOR: Stimulates glucose uptake via GLUT4, activates HK2, and promotes HIF-1α expression even under normoxic conditions
- p53 loss: Wild-type p53 normally promotes oxidative phosphorylation through SCO2 and TIGAR; loss of p53 shifts metabolism toward glycolysis
- PKM2: Cancer cells preferentially express the M2 isoform of pyruvate kinase, which has lower catalytic activity, causing glycolytic intermediates to accumulate for biosynthetic use
3. Gluconeogenesis
3.1 Why Gluconeogenesis?
Several tissues and cell types have an absolute requirement for glucose as their primary or sole fuel source. The brain consumes approximately 120 g of glucose per day (~60% of total body glucose utilization at rest), relying on continuous blood glucose supply. Red blood cells (erythrocytes) lack mitochondria entirely and are completely dependent on glycolysis. The renal medulla, lens and cornea of the eye, and exercising skeletal muscle also require glucose.
Since glycogen stores in the liver (~100 g) can only sustain blood glucose for about 12–18 hours during fasting, gluconeogenesis becomes essential during prolonged fasting, starvation, and intense exercise. Gluconeogenesis occurs primarily in the liver (~90%) and to a lesser extent in the kidney cortex (~10%).
3.2 Not Simply Reverse Glycolysis
Although gluconeogenesis uses seven of the ten glycolytic enzymes (the reversible steps), the three irreversible glycolytic reactions must be bypassed using four different enzymes. This is thermodynamically necessary because simply reversing the entire glycolytic pathway would be endergonic (\(\Delta G > 0\)).
The Four Bypass Reactions
Bypass 1: Pyruvate → Oxaloacetate (Mitochondrial)
Pyruvate carboxylase (biotin-dependent) converts pyruvate to oxaloacetate (OAA) in the mitochondrial matrix. This is an ATP-dependent carboxylation reaction. Pyruvate carboxylase is allosterically activated by acetyl-CoA, which signals that the TCA cycle is saturated and carbon should be diverted toward glucose synthesis.
\[\text{Pyruvate} + \text{CO}_2 + \text{ATP} \xrightarrow{\text{Pyruvate carboxylase}} \text{OAA} + \text{ADP} + P_i\]
Bypass 2: Oxaloacetate → Phosphoenolpyruvate (Cytosolic)
Phosphoenolpyruvate carboxykinase (PEPCK) decarboxylates and phosphorylates OAA to PEP using GTP. Since OAA cannot cross the mitochondrial membrane, it is first converted to malate (by mitochondrial malate dehydrogenase), transported to the cytosol, and re-oxidized to OAA (by cytosolic malate dehydrogenase) before PEPCK acts on it. This malate-aspartate shuttle also transfers reducing equivalents (NADH) to the cytosol.
\[\text{OAA} + \text{GTP} \xrightarrow{\text{PEPCK}} \text{PEP} + \text{CO}_2 + \text{GDP}\]
Bypass 3: Fructose-1,6-bisphosphate → Fructose-6-phosphate
Fructose-1,6-bisphosphatase (FBPase-1) catalyzes the hydrolytic removal of the C1 phosphate. This enzyme is allosterically inhibited by AMP and fructose-2,6-bisphosphate (F2,6BP) — the same signals that activate PFK-1. This reciprocal regulation ensures that glycolysis and gluconeogenesis do not operate simultaneously (which would constitute a futile cycle).
\[\text{F1,6BP} + \text{H}_2\text{O} \xrightarrow{\text{FBPase-1}} \text{F6P} + P_i\]
Bypass 4: Glucose-6-phosphate → Glucose
Glucose-6-phosphatase hydrolyzes G6P to free glucose in the lumen of the endoplasmic reticulum. This enzyme is found only in liver and kidney, which is why only these tissues can release free glucose into the blood. Muscle and brain lack glucose-6-phosphatase, so their G6P is committed to intracellular use.
\[\text{G6P} + \text{H}_2\text{O} \xrightarrow{\text{G6Pase}} \text{Glucose} + P_i\]
3.3 Energy Cost of Gluconeogenesis
Gluconeogenesis is energetically expensive, requiring 4 ATP + 2 GTP + 2 NADH per molecule of glucose synthesized from 2 pyruvate:
\[2\,\text{Pyruvate} + 4\,\text{ATP} + 2\,\text{GTP} + 2\,\text{NADH} + 2\,\text{H}^+ + 4\,\text{H}_2\text{O} \rightarrow \text{Glucose} + 4\,\text{ADP} + 2\,\text{GDP} + 6\,P_i + 2\,\text{NAD}^+\]
This corresponds to 6 ATP equivalents (since GTP ≈ ATP), compared to only 2 ATP produced by glycolysis. The difference of 4 high-energy phosphate bonds ensures that gluconeogenesis is thermodynamically favorable (\(\Delta G < 0\)).
3.4 Gluconeogenic Substrates
Lactate
Major substrate. Produced by muscle, RBCs, and other tissues. Converted to pyruvate by LDH in the liver. The Cori cycle continuously recycles lactate → glucose.
Glycerol
Released from triacylglycerol hydrolysis in adipose tissue. Phosphorylated by glycerol kinase to glycerol-3-phosphate, then oxidized to DHAP by glycerol-3-phosphate dehydrogenase. Enters gluconeogenesis at the triose phosphate level.
Glucogenic Amino Acids
All amino acids except leucine and lysine are glucogenic. They are transaminated or deaminated to pyruvate, OAA, α-ketoglutarate, succinyl-CoA, or fumarate — all of which can feed into gluconeogenesis. Alanine is the most important (glucose-alanine cycle).
3.5 Reciprocal Regulation: F2,6BP as Key Regulator
The bifunctional enzyme PFK-2/FBPase-2 produces and degrades fructose-2,6-bisphosphate (F2,6BP), the most potent allosteric regulator of both glycolysis and gluconeogenesis. The activity of this enzyme is controlled by phosphorylation:
| Condition | Hormone | PFK-2/FBPase-2 State | [F2,6BP] | Glycolysis | Gluconeogenesis |
|---|---|---|---|---|---|
| Fed state | Insulin ↑ | Dephosphorylated → PFK-2 active | High | ↑ Stimulated | ↓ Inhibited |
| Fasting | Glucagon ↑ | Phosphorylated (by PKA) → FBPase-2 active | Low | ↓ Inhibited | ↑ Stimulated |
Energetics Comparison
Glycolysis vs. gluconeogenesis — if both ran simultaneously, the net result would be a futile cycle consuming 4 ATP + 2 GTP per turn:
\[\text{Glycolysis: Glucose} \rightarrow 2\,\text{Pyruvate} + 2\,\text{ATP} + 2\,\text{NADH}\]
\[\text{Gluconeogenesis: } 2\,\text{Pyruvate} \rightarrow \text{Glucose} - 4\,\text{ATP} - 2\,\text{GTP} - 2\,\text{NADH}\]
\[\text{Futile cycle net: } -2\,\text{ATP} - 2\,\text{GTP} \text{ (wasted as heat)}\]
4. Glycogen Metabolism
4.1 Glycogen Structure
Glycogen is a highly branched polymer of glucose residues serving as the main storage form of glucose in animals. It consists of linear chains of glucose units connected by α(1→4) glycosidic bonds, with branch points every 8–12 residues via α(1→6) glycosidic bonds. A single glycogen granule can contain up to 55,000 glucose residues and has a molecular mass of up to 10⁸ Da. The highly branched structure provides many non-reducing ends for rapid simultaneous mobilization by glycogen phosphorylase.
The liver stores ~100 g of glycogen (up to 10% of its weight), which serves to maintain blood glucose between meals. Skeletal muscle stores ~400 g of glycogen (1–2% of muscle mass), which provides fuel exclusively for local muscular contraction (muscle lacks glucose-6-phosphatase).
4.2 Glycogenesis (Glycogen Synthesis)
Glycogen synthesis requires an activated form of glucose — UDP-glucose — as the glucosyl donor. The pathway proceeds through the following steps:
Step 1: UDP-Glucose Formation
Glucose-6-phosphate is converted to glucose-1-phosphate by phosphoglucomutase, then activated by UDP-glucose pyrophosphorylase using UTP:
\[\text{G1P} + \text{UTP} \rightarrow \text{UDP-glucose} + \text{PP}_i\]
The subsequent hydrolysis of PPᵢ by pyrophosphatase (PPᵢ → 2Pᵢ) drives this reaction to completion, effectively consuming 2 high-energy phosphate bonds per glucose added.
Step 2: Chain Elongation by Glycogen Synthase
Glycogen synthase transfers the glucosyl unit from UDP-glucose to the C4 hydroxyl of a terminal glucose residue, forming a new α(1→4) bond. This enzyme cannot initiate a new chain — it requires a pre-existing primer of at least 4 glucose residues attached to the protein glycogenin, which self-glucosylates to create the initial primer.
\[\text{Glycogen}_{(n)} + \text{UDP-glucose} \xrightarrow{\text{Glycogen synthase}} \text{Glycogen}_{(n+1)} + \text{UDP}\]
Step 3: Branch Creation by Branching Enzyme
When a chain reaches ~11 residues, the branching enzyme(amylo-α(1→4)→α(1→6) transglycosylase) transfers a terminal block of ~7 residues from a non-reducing end to the C6 hydroxyl of a glucose residue at least 4 residues away, creating a new α(1→6) branch point. Branching increases solubility and creates more non-reducing ends for rapid mobilization.
4.3 Glycogenolysis (Glycogen Breakdown)
Glycogen degradation is not the simple reverse of synthesis — it uses different enzymes and produces glucose-1-phosphate rather than free glucose.
Glycogen Phosphorylase
The key degradative enzyme, glycogen phosphorylase, cleaves α(1→4) bonds from the non-reducing ends by phosphorolysis (using Pᵢ rather than H₂O), releasing glucose-1-phosphate (G1P). This phosphorolytic cleavage is energetically advantageous because the sugar phosphate produced can enter glycolysis without an additional ATP investment. The enzyme requires pyridoxal phosphate (PLP, vitamin B₆) as a cofactor.
\[\text{Glycogen}_{(n)} + P_i \xrightarrow{\text{Phosphorylase}} \text{Glycogen}_{(n-1)} + \text{G1P}\]
Phosphorylase stops 4 residues from a branch point and cannot cleave α(1→6) bonds.
Debranching Enzyme
The debranching enzyme is a bifunctional protein with two catalytic activities: (1) oligo-α(1→4)→α(1→4)-glucan transferase moves a trisaccharide block from the branch to a nearby non-reducing end, exposing the single α(1→6)-linked residue; (2) amylo-α(1→6)-glucosidase hydrolyzes the remaining α(1→6) bond, releasing one free glucose. Thus ~10% of glycogen residues are released as free glucose and ~90% as G1P.
Phosphoglucomutase
Phosphoglucomutase converts G1P to G6P via a glucose-1,6-bisphosphate intermediate. The G6P can then enter glycolysis (in muscle) or be dephosphorylated to free glucose by glucose-6-phosphatase (in liver) for release into the bloodstream.
\[\text{G1P} \rightleftharpoons{\text{Phosphoglucomutase}} \text{G6P}\]
4.4 Hormonal Regulation: The Cascade
Glycogen metabolism is regulated by a classic hormonal signaling cascade involving epinephrine (muscle and liver) and glucagon (liver only). This was one of the first signal transduction cascades elucidated (Earl Sutherland, Nobel Prize 1971; Edmond Fischer and Edwin Krebs, Nobel Prize 1992).
The Glycogenolysis Cascade
1. Epinephrine/Glucagon binds to receptor (β-adrenergic/glucagon receptor)
2. Receptor activates Gₛ protein → activates adenylyl cyclase
3. Adenylyl cyclase converts ATP → cAMP (second messenger)
4. cAMP activates protein kinase A (PKA)
5. PKA phosphorylates and activates phosphorylase kinase
6. Phosphorylase kinase phosphorylates glycogen phosphorylase b → phosphorylase a (active)
Simultaneously:
7. PKA phosphorylates glycogen synthase a → synthase b (less active)
Result: coordinated activation of glycogenolysis and inhibition of glycogenesis
The cascade provides enormous signal amplification: a single hormone molecule can trigger the release of thousands of glucose molecules. Reversal occurs through protein phosphatases (especially PP1), which dephosphorylate all cascade components, returning the system to the basal state when hormone levels decline.
4.5 Glycogen Storage Diseases
Inherited deficiencies in enzymes of glycogen metabolism result in glycogen storage diseases (GSDs), characterized by abnormal glycogen accumulation or structure:
| Type | Name | Deficient Enzyme | Affected Organ(s) | Key Features |
|---|---|---|---|---|
| I | von Gierke | Glucose-6-phosphatase | Liver, kidney | Severe fasting hypoglycemia, hepatomegaly, lactic acidosis, hyperuricemia |
| II | Pompe | Lysosomal α-1,4-glucosidase (acid maltase) | All organs (lysosomes) | Cardiomegaly, muscle weakness, death by age 2 (infantile form) |
| III | Cori (Forbes) | Debranching enzyme | Liver, muscle | Milder form of type I; abnormally short outer branches |
| IV | Andersen | Branching enzyme | Liver | Long unbranched chains (amylopectin-like); cirrhosis, hepatic failure |
| V | McArdle | Muscle glycogen phosphorylase | Skeletal muscle | Exercise intolerance, painful muscle cramps, myoglobinuria; "second wind" phenomenon |
| VI | Hers | Liver glycogen phosphorylase | Liver | Mild hepatomegaly, mild hypoglycemia; generally benign |
5. Pentose Phosphate Pathway (PPP)
The pentose phosphate pathway (also called the hexose monophosphate shunt or phosphogluconate pathway) is an alternative route for glucose-6-phosphate oxidation that produces two essential products not provided by glycolysis: NADPH (reducing power for biosynthesis and antioxidant defense) and ribose-5-phosphate (for nucleotide and nucleic acid synthesis). The pathway occurs entirely in the cytoplasm and is especially active in liver, adipose tissue, adrenal cortex, mammary gland, and red blood cells.
5.1 Oxidative Phase
The oxidative phase is irreversible and consists of three reactions that convert G6P to ribulose-5-phosphate, generating 2 NADPH and releasing one CO₂ per G6P.
Reaction 1: G6P Dehydrogenase (Rate-Limiting)
Glucose-6-phosphate dehydrogenase (G6PD) catalyzes the oxidation of G6P to 6-phosphoglucono-δ-lactone, producing the first NADPH. This is the committed and rate-limiting step, regulated primarily by the [NADP⁺]/[NADPH] ratio. When NADPH is consumed (e.g., during fatty acid synthesis or glutathione reduction), NADP⁺ levels rise and stimulate G6PD.
\[\text{G6P} + \text{NADP}^+ \xrightarrow{\text{G6PD}} \text{6-Phosphoglucono-}\delta\text{-lactone} + \text{NADPH} + \text{H}^+\]
Reaction 2: Lactonase
6-Phosphoglucono-δ-lactone is hydrolyzed by lactonase to 6-phosphogluconate.
\[\text{6-Phosphoglucono-}\delta\text{-lactone} + \text{H}_2\text{O} \rightarrow \text{6-Phosphogluconate}\]
Reaction 3: 6-Phosphogluconate Dehydrogenase
6-Phosphogluconate is oxidatively decarboxylated to ribulose-5-phosphate, generating the second NADPH and releasing CO₂.
\[\text{6-Phosphogluconate} + \text{NADP}^+ \rightarrow \text{Ribulose-5-phosphate} + \text{CO}_2 + \text{NADPH}\]
Oxidative Phase Net Equation
\[\text{G6P} + 2\,\text{NADP}^+ + \text{H}_2\text{O} \rightarrow \text{Ribulose-5-phosphate} + 2\,\text{NADPH} + 2\,\text{H}^+ + \text{CO}_2\]
5.2 Non-Oxidative Phase
The non-oxidative phase consists of a series of reversible sugar interconversion reactions catalyzed by transketolase (requires TPP) and transaldolase. These reactions interconvert 3-, 4-, 5-, 6-, and 7-carbon sugar phosphates, connecting the PPP to glycolysis.
Key Reactions
- Ribulose-5-phosphate can be isomerized to ribose-5-phosphate (by phosphopentose isomerase) or epimerized to xylulose-5-phosphate (by phosphopentose epimerase)
- Transketolase (TPP-dependent): transfers a 2-carbon unit from a ketose to an aldose donor
— Xylulose-5-P + Ribose-5-P → Sedoheptulose-7-P + Glyceraldehyde-3-P
— Xylulose-5-P + Erythrose-4-P → Fructose-6-P + Glyceraldehyde-3-P - Transaldolase: transfers a 3-carbon unit
— Sedoheptulose-7-P + Glyceraldehyde-3-P → Erythrose-4-P + Fructose-6-P
Non-Oxidative Phase Net Equation
\[3\,\text{Ribulose-5-P} \rightleftharpoons 2\,\text{Fructose-6-P} + \text{Glyceraldehyde-3-P}\]
These products (F6P and G3P) are glycolytic intermediates — thus the PPP connects directly to glycolysis. The direction of the non-oxidative phase depends on the cell's relative needs for NADPH vs. ribose-5-phosphate vs. ATP.
5.3 Biological Purposes of the PPP
NADPH Production
NADPH is the primary cellular reductant for anabolic reactions: fatty acid synthesis, cholesterol synthesis, steroid hormone synthesis, and the reduction of oxidized glutathione (GSSG → 2 GSH) by glutathione reductase. In red blood cells, NADPH-dependent glutathione reduction is critical for protecting hemoglobin and membrane lipids from oxidative damage by reactive oxygen species (ROS).
Ribose-5-Phosphate
Ribose-5-phosphate is the sugar component of nucleotides (ATP, GTP, NAD⁺, FAD, CoA) and nucleic acids (RNA and DNA). Rapidly dividing cells (bone marrow, skin, gut epithelium, tumors) have high demand for ribose-5-phosphate for DNA replication. The non-oxidative phase can also run in reverse to generate ribose-5-phosphate from glycolytic intermediates when NADPH is not needed.
5.4 G6PD Deficiency
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzyme deficiency, affecting approximately 400 million people worldwide. It is an X-linked recessive disorder particularly prevalent in populations from malaria-endemic regions (Africa, Mediterranean, Southeast Asia) because heterozygous females have a selective advantage against Plasmodium falciparum malaria.
Without adequate G6PD activity, red blood cells cannot generate sufficient NADPH to maintain reduced glutathione (GSH). When challenged by oxidative stress (certain drugs like primaquine and sulfonamides, fava beans, or infections), RBCs undergo oxidative hemolysis. Hemoglobin precipitates form Heinz bodies, which damage the cell membrane, leading to hemolytic anemia.
Clinical Significance
G6PD deficiency illustrates the critical importance of NADPH in antioxidant defense. Red blood cells are especially vulnerable because they lack mitochondria and a nucleus — the PPP is their sole source of NADPH. The connection to malaria resistance is a classic example of balanced polymorphism in human genetics, analogous to sickle cell trait and HbS.
5.5 Connection to Glycolysis
The non-oxidative phase products — fructose-6-phosphate and glyceraldehyde-3-phosphate — are glycolytic intermediates. This connection allows the cell to adjust the flow of carbon between the PPP and glycolysis based on its metabolic needs:
- Need NADPH + ribose-5-P: Both phases operate normally
- Need NADPH only: Oxidative phase runs; R5P is recycled to G6P via non-oxidative phase (reversed) and gluconeogenic enzymes
- Need ribose-5-P only: Non-oxidative phase runs in reverse from F6P and G3P
- Need NADPH + ATP: Oxidative phase produces NADPH; F6P and G3P enter glycolysis for ATP
6. Blood Glucose Regulation
6.1 Normal Blood Glucose Levels
Blood glucose is maintained within a remarkably narrow range despite wide fluctuations in dietary intake and energy expenditure. The homeostatic set point is approximately:
Reference Ranges
- Normal fasting glucose: 3.9–5.6 mM (70–100 mg/dL)
- Impaired fasting glucose: 5.6–7.0 mM (100–125 mg/dL)
- Diabetes mellitus: ≥ 7.0 mM (≥ 126 mg/dL) on two occasions
- Postprandial (2h): < 7.8 mM (<140 mg/dL) normal; ≥ 11.1 mM (≥ 200 mg/dL) diabetic
- Hypoglycemia: < 3.0 mM (< 54 mg/dL) — clinically significant
\[\text{Conversion: } [\text{mg/dL}] = [\text{mM}] \times 18.02 \quad (\text{molecular weight of glucose} = 180.2 \text{ g/mol})\]
6.2 Glucose Transporters (GLUTs)
Glucose is a polar molecule that cannot freely diffuse across the hydrophobic lipid bilayer. Entry into cells requires specific membrane transport proteins. Two families of glucose transporters exist: the facilitative GLUTs (passive, down concentration gradient) and the sodium-glucose cotransporters (SGLTs, active, against gradient).
| Transporter | Tissue Distribution | K_m (mM) | Key Features |
|---|---|---|---|
| GLUT1 | Erythrocytes, brain (BBB), most tissues | ~1–2 | Basal glucose uptake; constitutive |
| GLUT2 | Liver, pancreatic β-cells, intestine, kidney | ~15–20 | High capacity, low affinity; glucose sensor in β-cells |
| GLUT3 | Neurons | ~1.4 | High affinity ensures neuronal glucose supply |
| GLUT4 | Skeletal muscle, adipose tissue, heart | ~5 | Insulin-responsive; stored in intracellular vesicles |
| GLUT5 | Small intestine, sperm | — | Primarily a fructose transporter |
| SGLT1/2 | Intestine (SGLT1), kidney proximal tubule (SGLT2) | — | Na⁺-dependent active transport; SGLT2 inhibitors (gliflozins) used in T2DM treatment |
6.3 Insulin Signaling
Insulin is secreted by pancreatic β-cells in response to elevated blood glucose (and amino acids, incretin hormones GLP-1 and GIP). It signals the fed state and promotes glucose uptake, utilization, and storage.
Insulin Signal Transduction Cascade
1. Insulin binds to the insulin receptor (a receptor tyrosine kinase, RTK)
2. Receptor autophosphorylation on tyrosine residues
3. Phosphorylated receptor recruits and phosphorylates insulin receptor substrates (IRS-1/2)
4. IRS activates phosphoinositide 3-kinase (PI3K)
5. PI3K produces PIP₃ → recruits and activates Akt (protein kinase B)
6. Akt triggers GLUT4 vesicle translocation to the plasma membrane
7. GLUT4 insertion increases glucose uptake in muscle and adipose tissue by ~10–20-fold
Beyond GLUT4 translocation, insulin promotes glucose utilization by:
- Activating glycogen synthase (via PP1 activation and GSK3 inhibition)
- Stimulating PFK-2 (increasing F2,6BP, stimulating glycolysis)
- Inducing glucokinase, PFK-1, and pyruvate kinase gene expression
- Activating pyruvate dehydrogenase (PDH) via PDH phosphatase
- Stimulating lipogenesis (acetyl-CoA carboxylase, fatty acid synthase)
- Suppressing PEPCK and glucose-6-phosphatase gene expression (inhibiting gluconeogenesis)
6.4 Glucagon Signaling
Glucagon is secreted by pancreatic α-cells in response to low blood glucose (and amino acids, especially during a protein-rich meal). It signals the fasted state and acts primarily on the liver.
Glucagon Signal Transduction
1. Glucagon binds to glucagon receptor (a G protein-coupled receptor, GPCR)
2. Gₛ protein activates adenylyl cyclase
3. Adenylyl cyclase converts ATP → cAMP
4. cAMP activates protein kinase A (PKA)
5. PKA phosphorylates multiple targets:
- Phosphorylase kinase → activates glycogen phosphorylase (glycogenolysis ↑)
- Glycogen synthase → inactivates it (glycogenesis ↓)
- PFK-2/FBPase-2 → activates FBPase-2 (F2,6BP ↓ → glycolysis ↓, gluconeogenesis ↑)
- Pyruvate kinase (L form) → inactivates it (glycolysis ↓)
6. PKA also activates CREB → induces PEPCK and G6Pase transcription (gluconeogenesis ↑)
6.5 Metabolic States: Fed vs. Fasted
| Parameter | Fed State (Absorptive) | Fasted State (Post-absorptive) |
|---|---|---|
| Dominant hormone | Insulin ↑ | Glucagon ↑ |
| Insulin/Glucagon ratio | High | Low |
| Glycolysis | ↑ Active | ↓ Suppressed |
| Gluconeogenesis | ↓ Suppressed | ↑ Active |
| Glycogenesis | ↑ Active | ↓ Suppressed |
| Glycogenolysis | ↓ Suppressed | ↑ Active |
| Lipogenesis | ↑ Active | ↓ Suppressed |
| β-Oxidation | ↓ Suppressed | ↑ Active |
| Ketogenesis | ↓ Suppressed | ↑ Active (prolonged fast) |
| Primary fuel (muscle) | Glucose | Fatty acids, ketone bodies |
| Primary fuel (brain) | Glucose | Glucose (ketone bodies in prolonged starvation) |
6.6 Diabetes Mellitus
Type 1 Diabetes Mellitus (T1DM)
Autoimmune destruction of pancreatic β-cells leads to absolute insulin deficiency. Usually presents in childhood/adolescence. Without insulin, tissues cannot take up glucose (despite hyperglycemia), and the body relies on fatty acid oxidation and ketogenesis. Uncontrolled T1DM leads to diabetic ketoacidosis (DKA) — a life-threatening metabolic emergency with blood pH < 7.3, ketonemia, and dehydration.
Treatment: lifelong exogenous insulin therapy.
Type 2 Diabetes Mellitus (T2DM)
Insulin resistance — target tissues (especially muscle, liver, adipose) show diminished response to insulin. Initially compensated by β-cell hyperinsulinemia, but β-cell failure eventually develops. Accounts for ~90% of all diabetes cases. Strongly associated with obesity, physical inactivity, and metabolic syndrome (central obesity, hypertension, dyslipidemia, hyperglycemia).
Treatment: lifestyle modification, metformin (activates AMPK, inhibits hepatic gluconeogenesis), sulfonylureas, GLP-1 receptor agonists, SGLT2 inhibitors, and eventually insulin.
Insulin Resistance Mechanisms
Insulin resistance in T2DM involves defects at multiple levels of the signaling cascade:
- Serine phosphorylation of IRS-1 (inhibitory, instead of activating tyrosine phosphorylation)
- Reduced PI3K activity and Akt phosphorylation
- Impaired GLUT4 translocation to the plasma membrane
- Chronic inflammation (TNF-α, IL-6 from adipose tissue) activates JNK and IKK pathways
- Lipotoxicity: excess intracellular lipids (diacylglycerol, ceramides) activate PKC isoforms that impair insulin signaling
- ER stress and mitochondrial dysfunction
HbA1c as a Diagnostic Marker
Glycated hemoglobin (HbA1c) is formed by the non-enzymatic glycation of hemoglobin by glucose. Since red blood cells have a lifespan of ~120 days, HbA1c reflects average blood glucose levels over the preceding 2–3 months. It is the gold standard for monitoring long-term glycemic control:
- Normal: HbA1c < 5.7% (~39 mmol/mol)
- Prediabetes: HbA1c 5.7–6.4% (39–47 mmol/mol)
- Diabetes: HbA1c ≥ 6.5% (≥ 48 mmol/mol)
- Target for diabetics: HbA1c < 7.0% (reduces microvascular complications)
\[\text{Estimated average glucose (mg/dL)} = 28.7 \times \text{HbA1c} - 46.7\]
6.7 Hypoglycemia
Hypoglycemia (blood glucose < 3.0 mM / 54 mg/dL) is a medical emergency because the brain depends on a continuous glucose supply and has very limited glycogen reserves (~5 g). Prolonged severe hypoglycemia causes neuronal damage, seizures, coma, and death.
Causes
- Insulin overdose (most common in diabetics)
- Sulfonylurea therapy
- Insulinoma (insulin-secreting tumor)
- Alcohol consumption (inhibits gluconeogenesis by depleting NAD⁺)
- Glycogen storage diseases (especially type I)
- Adrenal insufficiency (cortisol deficiency)
- Severe liver disease
- Prolonged starvation with depleted glycogen stores
Counter-Regulatory Response
The body mounts a hierarchical hormonal defense against hypoglycemia:
- ~3.8 mM: Insulin secretion decreases
- ~3.6 mM: Glucagon secretion increases
- ~3.4 mM: Epinephrine release (sympathetic symptoms: tremor, sweating, tachycardia)
- ~3.0 mM: Cortisol and growth hormone release
- <2.8 mM: Neuroglycopenic symptoms (confusion, seizures, loss of consciousness)
Alcohol and Hypoglycemia
Ethanol metabolism by alcohol dehydrogenase and aldehyde dehydrogenase generates excess NADH, shifting the NAD⁺/NADH ratio in the liver. This diverts pyruvate to lactate and oxaloacetate to malate, removing both key gluconeogenic substrates. The result is impaired hepatic gluconeogenesis, which can cause dangerous hypoglycemia — particularly in fasted individuals who have depleted their glycogen stores.
\[\text{Ethanol} + \text{NAD}^+ \xrightarrow{\text{ADH}} \text{Acetaldehyde} + \text{NADH} + \text{H}^+\]
\[\text{Acetaldehyde} + \text{NAD}^+ \xrightarrow{\text{ALDH}} \text{Acetate} + \text{NADH} + \text{H}^+\]
Chapter Summary
Glycolysis
Universal pathway: glucose → 2 pyruvate + 2 ATP + 2 NADH. Ten steps, three irreversible regulatory points (hexokinase, PFK-1, pyruvate kinase). PFK-1 is the most critical regulatory enzyme, controlled by F2,6BP, ATP, AMP, and citrate.
Pyruvate Fate
Three fates: acetyl-CoA (aerobic, PDH complex), lactate (anaerobic, LDH), or ethanol (fermentation). PDH complex uses 5 cofactors (TPP, lipoamide, CoA, FAD, NAD⁺) and is regulated by phosphorylation. Warburg effect in cancer: aerobic glycolysis.
Gluconeogenesis
Reverse synthesis of glucose from non-carbohydrate precursors (lactate, glycerol, amino acids). Four bypass enzymes replace the three irreversible glycolytic steps. Costs 4 ATP + 2 GTP per glucose. Reciprocally regulated with glycolysis via F2,6BP.
Glycogen Metabolism
Synthesis: UDP-glucose → glycogen synthase → α(1→4) chains + branching enzyme. Degradation: phosphorylase (G1P) + debranching enzyme. Hormonal cascade: epinephrine/glucagon → cAMP → PKA → coordinated activation/inactivation. Glycogen storage diseases.
Pentose Phosphate Pathway
Oxidative phase: 2 NADPH + ribose-5P + CO₂. Non-oxidative phase: sugar interconversions connecting to glycolysis. G6PD deficiency: hemolytic anemia, malaria resistance. NADPH for biosynthesis and antioxidant defense.
Blood Glucose Regulation
Insulin (fed state): RTK → IRS → PI3K → Akt → GLUT4. Glucagon (fasted state): GPCR → cAMP → PKA. Diabetes: T1DM (autoimmune, absolute deficiency) vs T2DM (insulin resistance, metabolic syndrome). HbA1c monitoring.